(Reuters) -Swedish medical equipment maker Getinge reported second-quarter core earnings above market expectations on Friday, driven by stable organic sales growth across its business areas and regions, and despite strong headwinds from U.S. tariffs and currency exchange effects.
Getinge’s adjusted earnings before interest, taxes and amortisation (EBITA) rose 0.8% to 989 million Swedish crowns ($101.7 million) in the quarter. Analysts were expecting 921 million crowns on average, a company-provided poll showed.
The maker of products for surgery, intensive care and sterilisation said the figure included a nearly 270 million crown loss caused by U.S. President Donald Trump’s import duties and negative currency effects compared to last year.
“We were once again successful in adjusting prices, but short term we have been forced to absorb most of the tariff costs,” CEO Mattias Perjos said in a statement.
“We are also analyzing opportunities to adapt the company’s costs and supply chain over time to this new reality,” Perjos added. Getinge makes more than a third of its sales in the United States.
When reporting its first quarter results in April, Getinge said that U.S. tariffs would not undo decades of global supply chains and ultimately most of their effects would be felt by hospitals and patients as suppliers push higher cost onto them through price increases.
Getinge reiterated its 2025 guidance for organic sales growth of between 2% and 5%.
($1 = 9.7257 Swedish crowns)
(Reporting by Marta Frąckowiak in Gdańsk; Editing by Milla Nissi-Prussak)
Comments